Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 09:00:07 03/07/2024 pm IST			5-day change	1st Jan Change
96.11 ^CHF	-0.36%		+0.19%	+13.24%

03/07	NOVARTIS AG : Berenberg sticks Neutral	ZD
02/07	Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement	DJ

NOVARTIS AG : JP Morgan reiterates its Neutral rating

January 03, 2024 at 07:30 pm IST

Richard Vosser from JP Morgan retains his Neutral opinion on the stock. The target price remains set at CHF 90.

Latest news about Novartis AG

NOVARTIS AG : Berenberg sticks Neutral	03/07	ZD
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement	03/07	DJ
NOVARTIS AG : Receives a Buy rating from Jefferies	02/07	ZD
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	02/07	ZD
Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector	02/07	MT
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	01/07	MT
New semester, new state of mind	01/07
NOVARTIS AG : Gets a Buy rating from Goldman Sachs	01/07	ZD
Foreign banks target Switzerland after UBS takeover of Credit Suisse	24/06	RE
NOVARTIS AG : Barclays reaffirms its Sell rating	24/06	ZD
INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	24/06	DP
Factbox-European companies cut jobs as economy sputters	21/06	RE
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	20/06	DP
Novartis: towards the filing of a buyout offer for MorphoSys	20/06	CF
MorphoSys Set to Delist Following Acquisition by Novartis	20/06	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	20/06	MT
Biotech company Morphosys will soon disappear from the stock exchange	20/06	RE
EU regulator mandates label updates on CAR-T cancer therapies	14/06	RE
PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	14/06	MT
Nkarta, Inc. Appoints George Vratsanos as Board of Directors	14/06	CI
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment	13/06	CI
NOVARTIS AG : JP Morgan reiterates its Neutral rating	11/06	ZD
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	07/06	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	07/06	MT
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation	06/06	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

18/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 10:54 pm IST

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 04:48 pm IST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 08:02 pm IST

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

106.7 USD

Average target price

110.3 USD

Spread / Average Target

+3.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+13.24%	22TCr
ELI LILLY AND COMPANY	+54.07%	82TCr
NOVO NORDISK A/S	+38.59%	63TCr
JOHNSON & JOHNSON	-7.05%	35TCr
MERCK & CO., INC.	+15.44%	32TCr
ABBVIE INC.	+5.72%	29TCr
ASTRAZENECA PLC	+13.40%	24TCr
ROCHE HOLDING AG	+0.61%	22TCr
AMGEN INC.	+7.42%	17TCr
PFIZER, INC.	-3.79%	16TCr

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : JP Morgan reiterates its Neutral rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals